Literature DB >> 11203420

Potencies of newer fluoroquinolones against Viridans group Streptococciisolated in 637 cases of bloodstream infection in the SENTRY Antimicrobial Surveillance Program (1997 to 1999): beyond Canada!

R N Jones, M A Pfaller.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11203420      PMCID: PMC90183          DOI: 10.1128/AAC.44.10.2922-2923.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  6 in total

1.  In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada.

Authors:  J C de Azavedo; L Trpeski; S Pong-Porter; S Matsumura; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients.

Authors:  F Alcaide; J Carratala; J Liñares; F Gudiol; R Martin
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

3.  Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers.

Authors:  D J Diekema; R N Jones; K V Rolston
Journal:  Diagn Microbiol Infect Dis       Date:  1999-05       Impact factor: 2.803

4.  Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals.

Authors:  L M Deshpande; D J Diekema; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1999-09       Impact factor: 2.803

5.  Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group.

Authors:  D J Diekema; M A Pfaller; R N Jones; G V Doern; K C Kugler; M L Beach; H S Sader
Journal:  Int J Antimicrob Agents       Date:  2000-02       Impact factor: 5.283

Review 6.  Bacteremia due to viridans streptococci in neutropenic patients: a review.

Authors:  P Y Bochud; T Calandra; P Francioli
Journal:  Am J Med       Date:  1994-09       Impact factor: 4.965

  6 in total
  1 in total

1.  Characterization of high-level daptomycin resistance in Viridans group Streptococci developed upon in vitro exposure to daptomycin.

Authors:  Ronda L Akins; Bradley D Katz; Catherine Monahan; Dylan Alexander
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.